Dr. René C.-Gaudreault, l. pharm., PhD, is a senior researcher at the Centre de recherche du CHU de Québec-Laval University. He is the director of a medicinal chemistry laboratory based at the Hôpital Saint-François d’Assise. In addition, he is a full professor in the Department of molecular medicine at the Laval University School of Medicine. Dr. C.-Gaudreault is the author and coauthor of over 100 publications in peer-reviewed journals, and the inventor and co-inventor of numerous patents. He is the recipient of several prizes and distinctions, notably the Frisen-Rygel Medal for an outstanding Canadian academic discovery leading to uniquely positioned commercialization opportunities. His research programs mainly focus on the design and development of new anti-inflammatory, antipsoriatic, and anticancer drugs for personalized therapies.
Development of new anticancer and anti-inflammatory drugs for personalized medicine
Cancer and inflammation-based diseases are major health concerns in Canada and worldwide. Despite important medical breakthroughs over the past 75 years, few treatments are efficient and devoid of deleterious effects. Consequently, new drugs and treatments are required to improve both the quality of life and the life expectancy of patients. It is in this context that Dr. Gaudreault’s laboratory is involved in the drug design and development of new anticancer agents and their prodrugs, and non-steroidal anti-inflammatory agents exhibiting suitable biopharmaceutical and pharmacodynamic properties for preclinical and clinical studies. In addition, Dr. Gaudreault’s team is involved in the determination of their mechanisms of action and their potential therapeutical applications, using various cellular and molecular pharmacology approaches to support the design and the optimization of the next generations of molecules. Dr. Gaudreault’s research programs involve several interrelated and complementary disciplines, including molecular design and modelling, medicinal chemistry, cell biology, molecular pharmacology, and animal experimentation. The outcomes of these projects will contribute to new and efficient drugs for applications in personalized medicine.
10, rue de l'Espinay
Canada G1L 3L5
Mesoporous Silica Nanoparticles: Selective Surface Functionalization for Optimal Relaxometric and Drug Loading PerformancesJournal Article
Adv Funct Mater, 24 (37), pp. 5911–5923, 2014, ISSN: 1616-301X.
Novel Cytocidal Substituted Phenyl 4-(2-Oxoimidazolidin-1-yl) Benzenesulfonates and Benzenesulfonamides with Affinity to the Colchicine-Binding Site: Is the Phenyl 2-Imidazolidinone Moiety a New Haptophore for the Design of New Antimitotics?Journal Article
Open J Med Chem, 5 , pp. 9-22, 2014, ISSN: 2164-313X.
Inactivation of the mTORC1-eukaryotic translation initiation factor 4E pathway alters stress granule formation.Journal Article
Mol Cell Biol, 33 (11), pp. 2285-301, 2013, ISSN: 0270-7306.
Inhibitory effects of cytoskeleton disrupting drugs and GDP-locked Rab mutants on bradykinin B₂ receptor cycling.Journal Article
Pharmacol Res, 71 , pp. 44-52, 2013, ISSN: 1043-6618.
Synthesis and growth inhibition activity of fluorinated derivatives of tamoxifen.Journal Article
Bioorg Med Chem Lett, 23 (6), pp. 1712-5, 2013, ISSN: 0960-894X.
Bradykinin receptors: agonists, antagonists, expression, signaling and adaptation to sustained stimulationJournal Article
J Angioedema, 1 (December), pp. 9-17, 2013, ISSN: 2365-5686.
Synthesis, biological evaluation, and structure-activity relationships of novel substituted N-phenyl ureidobenzenesulfonate derivatives blocking cell cycle progression in S-phase and inducing DNA double-strand breaks.Journal Article
J Med Chem, 55 (13), pp. 6194-208, 2012, ISSN: 0022-2623.
Imidazonaphthyridine systems (part 2): Functionalization of the phenyl ring linked to the pyridine pharmacophore and its replacement by a pyridinone ring produces intriguing differences in cytocidal activity.Journal Article
Eur J Med Chem, 52 , pp. 137-50, 2012, ISSN: 0223-5234.
Cation trapping by cellular acidic compartments: beyond the concept of lysosomotropic drugs.Journal Article
Toxicol Appl Pharmacol, 259 (1), pp. 1-12, 2012, ISSN: 0041-008X.
Substituted phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonamides as antimitotics. Antiproliferative, antiangiogenic and antitumoral activity, and quantitative structure-activity relationships.Journal Article
Eur J Med Chem, 46 (11), pp. 5327-42, 2011, ISSN: 0223-5234.
- Accélérer et rendre plus accessibles les tests précliniques en chimiothérapie et la radiothérapie du cancer, en utilisant le modèle de l'oeuf et des stratégies d'impression 3D, Subvention, Fonds de recherche du Québec - Nature et technologies, Projet de recherche en équipe, from 2020-04-01 to 2023-03-31
- Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
- Centre de recherche sur le cancer, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-05-01 to 2022-06-13
- Validation of Highly Potent Substituted Phenyl Alkylureas as Antipsoriatic Agents, Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2018-04-01 to 2021-03-31
Recently finished projects
- Comprendre le rôle des cellules immunitaires dans le psoriasis grâce au génie tissulaire, Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2014-04-01 to 2020-03-31
- Les phénylimidazolidones, de nouvelles molécules pour le traitement personnalisé des cancers du sein hormono- et chimiorésistants: du laboratoire vers la clinique., Subvention, Fondation de l'Université Laval, from 2015-10-01 to 2019-07-30
- Substituted phenyl alkylureas as new potent antipsoriatic drugs: Mechanism of action and structure-activity relationships., Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2015-07-01 to 2020-06-30